Journals / The Anatolian Journal of Cardiology / 2021 / Cilt: 25 - Sayı: 12

Evaluation of electrocardiogram and echocardiographic characteristics of pre-and post-operation of His bundle pacing: A comprehensive review and meta-analysis

Pages
845–857
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The overall implant success rate for HBP was 83.64%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Although His bundle pacing (HBP) has shown an improved therapeutic effect than conventional pacing in terms of reducing cardiovascular mortality, the basic characteristics of HBP has not been defined systematically.
📊
Key Findings & Data:Results: A total of 23 studies were included in the analysis.
💡
Conclusion & Impact:The overall implant success rate for HBP was 83.64%.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: Although His bundle pacing (HBP) has shown an improved therapeutic effect than conventional pacing in terms of reducing cardiovascular mortality, the basic characteristics of HBP has not been defined systematically. Therefore, a systematical review and meta-analysis on the HBP characteristics can be timely and favorable. In this study, we aimed to clarify the electrocardiogram and echocardiographic characteristics of the pre- and post-operation of HBP. Methods: Patients with HBP were exclusively included in this study. By evaluating their electrocardiogram characteristics, echocardiographic parameters, and cardiac function, the therapeutic effect of HBP was assessed. Results: A total of 23 studies were included in the analysis. The overall implant success rate for HBP was 83.64%. After HBP treatment, the paced QRS duration dropped from 147.73±19.46 ms to 116.84±17.32 ms (p<0.001). Left ventricular ejection fraction (LVEF) increased from 34.87%±9.62% to 46.40%±9.64% (p<0.001), and NYHA functional class improved from 2.90±0.57 to 1.78±0.58 within the HBP group (SMD﹣2.09; 95% CI﹣2.53,﹣1.64, p<0.001). Conclusion: HBP can significantly reduce the QRS duration, resulting in improvement of cardiac function in most patients. In addition, this approach is applicable to most patients without limitations.

🔖

Cite This Article

Lİ, M., REN, F., TİAN, J., YANG, K., ZHANG, J., SONG, H., YİN, D., CUİ, S. (2021). Evaluation of electrocardiogram and echocardiographic characteristics of pre-and post-operation of His bundle pacing: A comprehensive review and meta-analysis. The Anatolian Journal of Cardiology, Cilt: 25 - Sayı: 12, 845–857. https://ajindex.com/articles/365663

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Almufleh A, Marbach J, Chih S, Stadnick E, Davies R, Liu P, et al. Ejection fraction improvement and reverse remodeling achieved with Sacubitril/Valsartan in heart failure with reduced ejection fraction patients. Am J Cardiovasc Dis 2017; 7: 108-13
  2. Liu LW, Wu PC, Chiu MY, Tu PF, Fang CC. Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction. Acta Cardiol Sin 2020; 36: 125-32
  3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Rev Esp Cardiol (Engl Ed) 2016; 69: 1167. [Article in English, Spanish] 4. Kim GH, Uriel N, Burkhoff D. Reverse remodelling and myocardial recovery in heart failure. Nat Rev Cardiol 2018; 15: 83-96. [Crossref] 5. Leyva F, Nisam S, Auricchio A. 20 years of cardiac resynchronization therapy. J Am Coll Cardiol 2014; 64: 1047-58. [Crossref] 6. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49. [Crossref] 7. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al.; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004; 350: 2140-50. [Crossref] 8. Cvijić M, Antolič B, Klemen L, Zupan I. Repolarization heterogeneity in patients with cardiac resynchronization therapy and its relation to ventricular tachyarrhythmias. Heart Rhythm 2018; 15: 1784-90. [Crossref] 9. Ermis C, Seutter R, Zhu AX, Benditt LC, VanHeel L, Sakaguchi S, et al. Impact of upgrade to cardiac resynchronization therapy on ventricular arrhythmia frequency in patients with implantable cardioverter-defibrillators. J Am Coll Cardiol 2005; 46: 2258-63. [Crossref] 10. Medina-Ravell VA, Lankipalli RS, Yan GX, Antzelevitch C, Medina-Malpica NA, Medina-Malpica OA, et al. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes? Circulation 2003; 107: 740-6. [Crossref] 11. Fish JM, Di Di